Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand.
Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand.
复制标题
DOI：
10.1371/journal.pone.0246864
复制
发表时间：
2021
期刊：
影响因子：
3.7
通讯作者：
Hemachudha T
中科院分区：
文献类型：
--
作者：
Putcharoen O;Wacharapluesadee S;Chia WN;Paitoonpong L;Tan CW;Suwanpimolkul G;Jantarabenjakul W;Ruchisrisarod C;Wanthong P;Sophonphan J;Chariyavilaskul P;Wang LF;Hemachudha T
中和抗体（NAb）的存在是大多数病毒感染的保护性免疫的指标。新开发的替代病毒中和试验（sVNT）能够以不依赖于同种型的方式检测靶向总受体结合结构域的NAb，从而提高了检测灵敏度。因此，具有低IgM/ IgG抗体水平的标本在sVNT中显示出强中和活性。本研究旨在测量PCR确认的COVID-19患者中通过sVNT测量的NAb抑制%。测定sVNT诊断SARS-CoV-2感染的敏感性及其动力学。本研究纳入了97例PCR证实的SARS-CoV-2感染患者。大多数患者年龄在21-40岁（67%），63%症状轻微。sVNT诊断SARS-CoV-2感染的敏感性为99%（95%CI 94.4-100%），特异性为100%（95%CI 98.3-100%）。症状发作前和7天后收集的样本sVNT的阴性预测值分别为99.5%（95%CI 97.4-100%）和100%（95%CI 93.8-100%）。第8-14天的抑制水平显著高于第0-7天（p<0.001）。按COVID-19症状严重程度列出的中位%抑制值分别为79.9%（四分位距（IQR）49.7-91.8%）; 89.0%（IQR 71.2-92.4%）;和86.6%（IQR 69.5-92.8%）（轻度、中度和重度/危重症状）。重度组sVNT %抑制的中位水平显著高于轻度组（p = 0.05）。sVNT是SARS-CoV-2感染的实用和稳健的血清学检测，不需要专门的生物安全防护。它可用于临床辅助诊断早期和晚期感染，特别是在实时RT-PCR结果为弱阴性或弱阳性的情况下，并确定患者对SARS-CoV-2感染的保护性免疫应答。
The presence of neutralizing antibodies (NAbs) is an indicator of protective immunity for most viral infections. A newly developed surrogate viral neutralization assay (sVNT) offers the ability to detect total receptor binding domain-targeting NAbs in an isotype-independent manner, increasing the test sensitivity. Thus, specimens with low IgM/ IgG antibody levels showed strong neutralization activity in sVNT. This study aimed to measure the %inhibition of NAbs measured by sVNT in PCR-confirmed COVID-19 patients. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection and its kinetics were determined. Ninety-seven patients with PCR-confirmed SARS-CoV-2 infection were included in this study. Majority of the patients were 21–40 years old (67%) and 63% had mild symptoms. The sensitivity of sVNT for the diagnosis of SARS-CoV-2 infection was 99% (95% confidence interval (CI) 94.4–100%) and the specificity was 100% (95% CI 98.3–100%). The negative predictive value of sVNT from the samples collected before and after 7 days of symptom onset was 99.5% (95% CI 97.4–100%) and 100% (95% CI 93.8–100%), respectively. The level of inhibition at days 8–14 were significantly higher than days 0–7 (p<0.001). The median %inhibition values by severity of COVID-19 symptoms were 79.9% (interquartile range (IQR) 49.7–91.8%); 89.0% (IQR 71.2–92.4%); and 86.6% (IQR 69.5–92.8%), for mild, moderate and severe/critical symptoms respectively. The median level of sVNT %inhibition of severe was significantly higher than the mild group (p = 0.05). The sVNT is a practical and robust serological test for SARS-CoV-2 infection and does not require specialized biosafety containment. It can be used clinically to aid diagnosis in both early and late infection especially in cases when the real-time RT-PCR results in weakly negative or weakly positive, and to determine the protective immune response from SARS-CoV-2 infection in patients.
登录
查看更多内容
影响因子：
9.4
作者：
Addetia A;Crawford KHD;Dingens A;Zhu H;Roychoudhury P;Huang ML;Jerome KR;Bloom JD;Greninger AL
通讯作者：
Greninger AL
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
15.9
作者：
Wang, Yanqun;Zhang, Lu;Zhao, Jincun
通讯作者：
Zhao, Jincun
DOI：
10.1016/s0140-6736(20)31605-6
发表时间：
2020-08-15
期刊：
Lancet (London, England)
影响因子：
--
作者：
Zhu FC;Guan XH;Li YH;Huang JY;Jiang T;Hou LH;Li JX;Yang BF;Wang L;Wang WJ;Wu SP;Wang Z;Wu XH;Xu JJ;Zhang Z;Jia SY;Wang BS;Hu Y;Liu JJ;Zhang J;Qian XA;Li Q;Pan HX;Jiang HD;Deng P;Gou JB;Wang XW;Wang XH;Chen W
通讯作者：
Chen W
DOI：
10.1001/jama.2020.6775
发表时间：
2020-01-01
期刊：
JAMA, Journal of the American Medical Association
影响因子：
--
作者：
Richardson, Safiya;Hirsch, Jamie S.;,
通讯作者：
,